Comprehensive assessment shows comparable pharmacokinetics of ribociclib in Asian and non-Asian patients, suggesting current dosing guidelines are adequate.
This comprehensive ethnicity assessment suggests comparable PK of ribociclib between Asian and non-Asian patients and supports current dose recommendations in Asian patients.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: